Stories

02.15.24

READDI expertise guides 100 Days Mission Therapeutics Roadmap

The Roadmap’s headline goal mirrors READDI’s top goal: Develop at least two Phase-2 ready candidates for each virus family with pandemic potential.

02.08.24

READDI and SAS get ahead of the next pandemic with AI and machine-learning fueled drug discovery

01.24.24

Global coalition warns of bare R&D pipeline for pathogens with pandemic potential

01.22.24

READDI is filling the R&D pipeline for pandemic pathogens

11.13.23

Comprehensive antiviral landscape assessment guides R&D

11.08.23

Viral threats surge in a warming world

10.16.23

Why READDI Inc.?

09.27.23

Symposium underscores READDI’s role in ‘marathon of preparedness’

09.18.23

Expert group makes strong case for medical-countermeasures network

08.28.23

A bipartisan opportunity to strengthen America’s pandemic security

08.21.23

How READDI develops drugs for viruses that don’t yet exist

07.20.23

READDI contributes to alliance in accelerating antiviral drug development

05.20.22

READDI receives $65M grant from NIH to establish Antiviral Drug Discovery (AViDD) Center

02.11.22

READDI receives $18M in from the N.C. General Assembly

11.08.21

READDI awarded $5M by RTI’s Forethought Research Collaboration Challenge

09.14.21